References 1 Salehi S, Abedi A, Balakrishnan S, et al. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. Am J
Irodalom 1 Amicucci M，Canesi M，Rostagno E等。我们如何保护患者：意大利儿科onco-heragology单位对COVID
Irodalom 1 Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis and angiogenesis inCOVID-19. N Engl J Med. 2020
在前18个月COVID-19大流行，AkadémiaiKiadó发表了近180篇，紧密或松散相关的文章。自然，其中大多数属于医学和健康科学或生物学和生命科学。万博电竞app限制登录而且，还有
A COVID–19 patológiája.
Halálok SARS-CoV-2-fertőzésben: vírusfertőzésben vagy vírusfertőzéssel?
Pathology of COVID-19.
SARS-COV-2感染中的死亡原因：病毒感染或其他患有SARS-COV-2的慢性疾病（死亡“ in”或“ with” Covid-19）
-020-02949-8 2 Benedetti, C., Waldman, M., Zaza, G., Riella, L.V., & Cravedi, P. (2020)COVID-19和肾脏：更新。Front Med（Lausanne），第1卷。7.第423号。https：//dx.doi.org/10.3389/fmed.2020
COVID–19 primer immunhiányos betegekben
新冠肺炎in patients with primary immunodeficiency
–531。4 Ho He，Mathew S，Peluso MJ等。临床结果和特征COVID-19纽约市初级免疫缺陷的患者。J过敏临床免疫实践。2021;9：490–493.e2
References 1 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a
References 1 Váradi A, Ferenci T, Falus A. The coronavirus-inducedCOVID–19 pandemic. Previous experiences and scientific evidences at the end of March
References 1 Governmental decree 1012/2020. (I. 31.) on establishing Executive board on defense againstCOVID–19. [A Kormány 1012/2020. (1. 31.) Korm
Vírusellenes terápiás lehetőségek COVID–19 fertőzés kezelésére
Antiviral therapies for COVID-19 infections
Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to ModerateCOVID-19：A Randomized Clinical Trial. JAMA, Vol. 325. No. 7. pp. 632
